Breaking: Adaptimmune Therapeutics PLC – ADR Increases Again; Strong Momentum for Buyers

Breaking: Adaptimmune Therapeutics PLC   ADR Increases Again; Strong Momentum for Buyers

The stock of Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) is a huge mover today! About 81,820 shares traded hands. Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) has declined 29.36% since March 7, 2016 and is downtrending. It has underperformed by 36.95% the S&P500.
The move comes after 9 months positive chart setup for the $449.69M company. It was reported on Oct, 10 by We have $12.33 PT which if reached, will make NASDAQ:ADAP worth $373.24M more.

Analysts await Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) to report earnings on November, 11. They expect $-0.23 earnings per share, down 1,050.00% or $0.21 from last year’s $-0.02 per share. After $-0.31 actual earnings per share reported by Adaptimmune Therapeutics PLC – ADR for the previous quarter, Wall Street now forecasts -25.81% EPS growth.

According to Zacks Investment Research, “Adaptimmune Therapeutics plc is a biopharmaceutical company. The Company is focused on cancer immunotherapy products based on T-cell receptor platform. Adaptimmune Therapeutics plc is based in Abingdon, United Kingdom.”

More notable recent Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) news were published by: which released: “Adaptimmune Therapeutics PLC ADR” on April 14, 2015, also with their article: “DOW JONES, A NEWS CORP COMPANY” published on November 29, 2014, published: “Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) Basic Consolidated EPS At $-0 …” on October 07, 2016. More interesting news about Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) were released by: and their article: “Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) Basic Net EPS Stands At $-0.3783” published on September 17, 2016 as well as‘s news article titled: “Quarterly EPS Estimate For Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) Is …” with publication date: September 23, 2016.

ADAP Company Profile

Adaptimmune Therapeutics plc, incorporated on December 03, 2014, is a clinical-stage biopharmaceutical company. The Firm is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Firm has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients. The Firm develops TCRs to increase the affinity to cancer specific peptides in order to destroy cancer cells in patients.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: ,

Leave a Comment